NaturalShrimp Issued Patent Number 11,297,809 for Ammonia Control in a Recirculating Aquaculture System
NaturalShrimp, Inc. (OTCQB: SHMP) announced the issuance of a new patent on April 12, 2022, for its electrocoagulation technology applied in aquaculture. This patent, 11,297,809, enhances their existing system for ammonia control in shrimp production. It builds upon the original patent awarded in 2018, which NaturalShrimp fully owns since acquiring F&T Water Solutions in May 2021. The new patent strengthens the company’s market position and legal protection for its innovative aquaculture methods, according to CTO Tom Untermeyer.
- Acquisition of patent 10,163,199 enhances competitive edge in aquaculture.
- New patent 11,297,809 improves ammonia control, potentially boosting production efficiency.
- None.
Patent Incorporates New Novel Improvements to Recirculating Aquaculture System and Treatment Method for Aquatic Species
DALLAS, TX, April 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – NaturalShrimp, Inc. (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), was awarded a new patent on April 12, 2022 from the United States Patent and Trademark Office. The new patent expands the Company’s electrocoagulation technology as applied to aquaculture both domestically and internationally.
The original United States patent 10,163,199 “Recirculating Aquaculture System and Treatment Method for Aquatic Species” was awarded jointly to NaturalShrimp, Inc. and F&T Water Solutions, LLC on December 25, 2018. NaturalShrimp, Inc. acquired the assets of F&T Water Solutions, LLC on May 20, 2021, therefore providing NaturalShrimp, Inc. with
NaturalShrimp’s solely owned new patent 11,297,809 “Ammonia Control in a Recirculating Aquaculture System” includes enhancements to the original patent based on new novel improvements realized since applying the electrocoagulation technology for shrimp production over the last several years. This new patent further strengthens the legal protection of the Company’s electrocoagulation technology platform as applied to aquaculture both domestically and internationally.
“The issuance of this second patent reinforces NaturalShrimp’s leadership role in applying our customized electrocoagulation technology for maintaining water quality within recirculating aquaculture systems,” said Tom Untermeyer, CTO of NaturalShrimp. “We will continue to apply for more patents as needed to protect our technology for the Company and for our shareholders.”
About NaturalShrimp
NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp. For more information visit www.naturalshrimp.com.
Forward-Looking Statements
This press release includes a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2021, any of which may cause our company’s or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements.
Investor Relations Contact
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
SHMP@mzgroup.us
FAQ
What is the new patent awarded to NaturalShrimp, Inc. (SHMP)?
When was the new patent for NaturalShrimp (SHMP) issued?
How does the new patent benefit NaturalShrimp (SHMP)?
What technology does NaturalShrimp (SHMP) specialize in?
What is the significance of the patent acquisition for NaturalShrimp (SHMP)?
